Abstract
A 69-year-old man with castration-resistant prostate cancer (CRPC) received docetaxel and a corticosteroid. After the third cycle of docetaxel administration, he presented with dyspnea, cough, sputum, and fever of 39.2°C. The chest X-ray and chest computed tomography (CT) revealed a diffuse reticulonodular shadow in both lungs, which suggested interstitial pneumonitis. Initially, we used empiric broad-spectrum antibiotics and high-dose corticosteroids. However, his condition progressively became worse and he was transferred to the intensive care unit, intubated, and placed on mechanical ventilation. He died 4 days after hospital admission. Here we report this case of fatal interstitial pneumonitis after treatment with docetaxel for CRPC. We briefly consider docetaxel-induced pneumonitis to make physicians aware of the possibility of pulmonary toxicity so that appropriate treatment can be begun as soon as possible. ©The Korean Urological Association, 2012.
Author supplied keywords
Cite
CITATION STYLE
Min, B. D., Kang, H. W., Kim, W. T., Kim, Y. J., Yun, S. J., Lee, S. C., & Kim, W. J. (2012). Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer. Korean Journal of Urology, 53(5), 371–374. https://doi.org/10.4111/kju.2012.53.5.371
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.